Cargando…

ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China

OBJECTIVE: Small cell lung cancer (SCLC) is one of the most aggressive malignancies characterized by neuroendocrine (NE) differentiation. The Delta‐like protein 3 (DLL3), as a direct downstream target of ASCL1, is involved in NE differentiation and carcinogenesis of SCLC. This study aims to investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Chunfang, Dong, Jiyan, Liu, Li, Liu, Jingbo, Sun, Xujie, Teng, Fei, Wang, Xin, Ying, Jianming, Li, Junling, Xing, Puyuan, Yang, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807256/ https://www.ncbi.nlm.nih.gov/pubmed/34931456 http://dx.doi.org/10.1111/1759-7714.14249

Ejemplares similares

Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer
por: Wei, Jiacong, et al.
Publicado: (2020)

Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection
por: Guo, Yiying, et al.
Publicado: (2020)

Prognostic significance of YAP1 expression and its association with neuroendocrine markers in resected pulmonary large cell neuroendocrine carcinoma (LCNEC)
por: Sun, Xujie, et al.
Publicado: (2022)

Clinical significance of ALDH1A1 expression and its association with E-cadherin and N-cadherin in resected large cell neuroendocrine carcinoma
por: Zhang, Jinyao, et al.
Publicado: (2022)

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy
por: Tendler, Salomon, et al.
Publicado: (2020)

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
por: Sun, Dantong, et al.
Publicado: (2021)

Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain‐only relapse versus synchronous extracranial relapse
por: Xu, Fei, et al.
Publicado: (2023)

Bufalin inhibits gastric cancer invasion and metastasis by down-regulating Wnt/ASCL2 expression
por: Wang, Jie, et al.
Publicado: (2018)

Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences
por: Xu, Fei, et al.
Publicado: (2022)

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer
por: Drouillard, A, et al.
Publicado: (2016)

The N terminus of Ascl1 underlies differing proneural activity of mouse and Xenopus Ascl1 proteins
por: Hardwick, Laura J.A., et al.
Publicado: (2018)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

Clinical implications of DLL4 expression in gastric cancer
por: Ishigami, Sumiya, et al.
Publicado: (2013)

Apatinib as maintenance therapy following standard first‐line chemotherapy in extensive disease small cell lung cancer: A phase II single‐arm trial
por: Teng, Fei, et al.
Publicado: (2022)

CD247 expression is associated with differentiation and classification in ovarian cancer
por: Ye, Wenfeng, et al.
Publicado: (2019)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2022)

Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo
por: Geffers, Insa, et al.
Publicado: (2007)

Context-Dependent Functional Divergence of the Notch Ligands DLL1 and DLL4 In Vivo
por: Preuße, Kristina, et al.
Publicado: (2015)

Ascl2 activation by YAP1/KLF5 ensures the self-renewability of colon cancer progenitor cells
por: Wei, Xiaolong, et al.
Publicado: (2017)

DLL3: an emerging target in small cell lung cancer
por: Owen, Dwight H., et al.
Publicado: (2019)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
por: Li, Yan, et al.
Publicado: (2022)

Health Tract, No. 247: Filth and Purity
Publicado: (1866)

Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer
por: Yim, Hyun Ee, et al.
Publicado: (2021)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
por: Xu, Ziyi, et al.
Publicado: (2022)

ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer
por: Zhang, Dan, et al.
Publicado: (2023)

Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma
por: Li, Lijuan, et al.
Publicado: (2019)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)
por: Xie, Tongji, et al.
Publicado: (2020)

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
por: Mu, Yuxin, et al.
Publicado: (2019)

Potential Mechanism of Immune Evasion Associated with the Master Regulator ASCL2 in Microsatellite Stability in Colorectal Cancer
por: Yang, Qian, et al.
Publicado: (2021)

Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine
por: Shimizu, Hiromichi, et al.
Publicado: (2014)

Expressions and Prognostic Values of Notch3 and DLL4 in Human Breast Cancer
por: Wang, Lin, et al.
Publicado: (2023)

Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA
por: Li, Yan, et al.
Publicado: (2022)

Anti-DLL4, a cancer therapeutic with multiple mechanisms of action
por: Gurney, Austin, et al.
Publicado: (2011)

The role of DLL1 in long-term vascular normalization and cancer immunotherapy
por: Wu, Qiaozhen, et al.
Publicado: (2021)

DLL3 regulates Notch signaling in small cell lung cancer
por: Kim, Jun W., et al.
Publicado: (2022)

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
por: Mu, Yuxin, et al.
Publicado: (2020)

High expression of Dll4 and CD44V6 is associated with clinicopathological characteristics and poor prognosis in osteosarcoma patients
por: Xie, Haiyang, et al.
Publicado: (2021)

Clinical effect of pemetrexed as the first‐line treatment in Chinese patients with advanced anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Ma, Di, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u9nflo09qj9pcntahg80acj4h9